Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018162846) PREVENTION OF THE ADVERSE EFFECTS OF MITOCHONDRIAL REACTIVE OXYGEN SPECIES USING A MITOCHONDRIAL ROS PRODUCTION-SPECIFIC INHIBITOR
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/162846 International Application No.: PCT/FR2018/050522
Publication Date: 13.09.2018 International Filing Date: 07.03.2018
IPC:
A61P 3/10 (2006.01) ,A61K 31/385 (2006.01) ,A61P 19/04 (2006.01) ,A61P 11/00 (2006.01) ,A61P 27/06 (2006.01) ,A61K 31/40 (2006.01) ,A61K 31/455 (2006.01) ,A61K 45/06 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
08
for glucose homeostasis
10
for hyperglycaemia, e.g. antidiabetics
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
38
having sulfur as a ring hetero atom
385
having two or more sulfur atoms in the same ring
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19
Drugs for skeletal disorders
04
for non-specific disorders of the connective tissue
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11
Drugs for disorders of the respiratory system
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27
Drugs for disorders of the senses
02
Ophthalmic agents
06
Antiglaucoma agents or miotics
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
40
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
455
Nicotinic acid, i.e. niacin; Derivatives thereof, e.g. esters, amides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Applicants:
CHILDS, Marc [FR/FR]; FR
PETITJEAN, Olivier [FR/FR]; FR
PETITJEAN, Guillaume [FR/FR]; FR
PETITJEAN, Elodie [FR/FR]; FR
PETITJEAN, Grégoire [FR/FR]; FR
SAUZIERES, Jacques [FR/FR]; FR
Inventors:
CHILDS, Marc; FR
PETITJEAN, Olivier; FR
PETITJEAN, Guillaume; FR
PETITJEAN, Elodie; FR
PETITJEAN, Grégoire; FR
Agent:
BREESE, Pierre; FR
Priority Data:
FR 17/5183707.03.2017FR
FR 17/5183807.03.2017FR
FR 17/5184007.03.2017FR
Title (EN) PREVENTION OF THE ADVERSE EFFECTS OF MITOCHONDRIAL REACTIVE OXYGEN SPECIES USING A MITOCHONDRIAL ROS PRODUCTION-SPECIFIC INHIBITOR
(FR) PRÉVENTION DES EFFETS ADVERSES DES ESPECES REACTIVES DE L'OXYGENE D'ORIGINE MITOCHONDRIALE À L'AIDE D'UN INHIBITEUR SPECIFIQUE DE LA PRODUCTION DE ROS D'ORIGINE MITOCHONDRIALE
Abstract:
(EN) The present invention relates to the prevention of diseases involving reactive oxygen species (ROS) of mitochondrial origin. More specifically, the invention relates to the use of an inhibitor of the production of mitochondrial ROS, in particular anethole trithione, in order to prevent the negative effects of reactive oxygen species of mitochondrial origin.
(FR) La présente invention a trait à la prévention des maladies dans lesquelles sont impliquées les espèces réactives de l'oxygène (ou ROS) d'origine mitochondriale. Elle concerne plus particulièrement l'utilisation d'un inhibiteur de la production de ROS mitochondriaux, en particulier de l'anéthole trithione, pour prévenir les effets négatifs des espèces réactives de l'oxygène d'origine mitochondriale.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: French (FR)
Filing Language: French (FR)